Our overall Program is focused on understanding the oncogenomic changes in myeloma central to disease pathogenesis which impact clinical outcome. We have proposed two large clinical trials;first to evaluate the role of transplant in the era of novel therapies;and second to evaluate progression from MGUS/SMM to active MM, which will accrue 1000 patients and 1210 patients, respectively, both in France and the United States. A critical aspect of obtaining robust ongenomic data is to have centralized and uniform processing and analysis of samples with established SOPs. Specifically, samples will be obtained from patients enrolled on the randomized trial evaluating lenalidomide bortezomib and dexamethasone (RVD) with or without high dose therapy and autotransplant at time of diagnosis (Project 2) and at relapse (Project 4);and from patients with monoclonal gammopathy of undetermined significance/smoldering MM (MGUS/SMM) at time of study entry and progression (Project 2). In each case, tumor cells versus normal cells will be isolated in Core B using well established procedures. Core C will perform DNA, RNA, and microRNA analyses on these samples. In addition, this Core will perform genomic analyses on preclinical samples, specifically evaluating changes in RNA and miRNA resulting from gain and loss of gene function, as well as before and after novel targeted therapies. This Core will provide a detailed catalog of gains or losses in DNA by using Genome Wide Human SNP 6.0 array. Levels of mRNA expression and splicing of all genes will be assessed using whole transcript GeneChip? Human Exon 1.0 ST array. Micro RNA (miRNA) profile will be established using qPCR-based miRNA arrays. This core has also interacted closely with investigators in Core E for bioinformatic support and data analysis, which is essential for the success of our proposed studies. This core has and will continue to help identify novel targets and validate targeted therapies in preclinical studies in Project 3. The following 3 Specific Aims will be pursued: to assess changes in DNA by high density SNP array analysis (Specific Aim 1);to evaluate expression profile and alternate splicing using Exon 1.0 ST array (Specific Aim 2);to profile miRNA using high density qPCR array (Specific Aim 3). Core C is therefore an essential and integral component to meet our goals.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-J)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Dana-Farber Cancer Institute
United States
Zip Code
Fulciniti, Mariateresa; Martinez-Lopez, Joaquin; Senapedis, William et al. (2017) Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma. Blood 129:2233-2245
Magrangeas, Florence; Kuiper, Rowan; Avet-Loiseau, Hervé et al. (2016) A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma. Clin Cancer Res 22:4350-4355
Ohguchi, Hiroto; Hideshima, Teru; Bhasin, Manoj K et al. (2016) The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival. Nat Commun 7:10258
Stroopinsky, Dina; Kufe, Donald; Avigan, David (2016) MUC1 in hematological malignancies. Leuk Lymphoma 57:2489-98
Richardson, Paul G; Hungria, Vânia T M; Yoon, Sung-Soo et al. (2016) Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. Blood 127:713-21
Fulciniti, M; Amodio, N; Bandi, R L et al. (2016) miR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth. Blood Cancer J 6:e380
Szalat, Raphael; Avet-Loiseau, Herve; Munshi, Nikhil C (2016) Gene Expression Profiles in Myeloma: Ready for the Real World? Clin Cancer Res 22:5434-5442
Amodio, Nicola; Stamato, Maria Angelica; Gullà, Anna Maria et al. (2016) Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma. Mol Cancer Ther 15:1364-75
Xu, Lian; Hunter, Zachary R; Tsakmaklis, Nicholas et al. (2016) Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia. Br J Haematol 172:735-44
Gullà, Annamaria; Di Martino, Maria Teresa; Gallo Cantafio, Maria Eugenia et al. (2016) A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells. Clin Cancer Res 22:1222-33

Showing the most recent 10 out of 180 publications